Furthermore, in some countries the access to first line ICI-based combinatorial treatment strategies in NSCLC will not be easily and shortly incorporated in clinical practice, especially for patients with high PD-L1 expression. The gene discussed is CD274; the disease is non-small cell lung carcinoma.